# Association between methylation quantitative trait loci and colorectal cancer risk, survival and cancer recurrence

**Authors:** Ines Mesa-Eguiagaray, Andrii Iakovliev, Xue Li, Maria Timofeeva, Yazhou He, Xiaomeng Zhang, Farhat V. N. Din, Susan M. Farrington, Athina Spiliopoulou, Malcolm G. Dunlop, Evropi Theodoratou

PMC · DOI: 10.1038/s41416-025-03064-8 · British Journal of Cancer · 2025-06-12

## TL;DR

This study explores how DNA methylation patterns linked to genetic variants are associated with colorectal cancer risk but not with survival or recurrence.

## Contribution

The study identifies 19 methylation quantitative trait loci (mQTLs) associated with colorectal cancer risk, including two novel genomic regions.

## Key findings

- 19 mQTLs in 10 genomic regions were associated with colorectal cancer risk.
- Two novel regions were mapped to MDGA2 and STARD3 with strong statistical significance.
- No associations were found between mQTLs and CRC survival or recurrence after correction.

## Abstract

Epigenetic changes contribute to colorectal cancer (CRC) pathogenesis. We investigated whether methylation quantitative trait loci (mQTLs) are associated with CRC risk, survival and recurrence.

Using a well-characterised Scottish case-control study (6821 CRC cases, 14,692 controls), we derived 118,982 mQTLs based on the Genetics of DNA Methylation Consortium (GoDMC). Association analysis between mQTLs and CRC risk, survival and recurrence was performed using logistic regression or Cox models respectively. Additionally, colocalisation analysis was performed.

19 mQTLs within 10 distinct genomic regions were associated with CRC risk. Two novel regions were mapped to MDGA2 (p value = \documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$3.0 \times\!{10}^{-6}$$\end{document}3.0×10−6) and STARD3 (p value = \documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$5.6 \times\!{10}^{-6}$$\end{document}5.6×10−6). Four regions mapped to POU5F1B, POU2AF2 (c11orf53)/POU2AF3 (COLCA2), GREM1 and CABLES2 were previously identified. Four regions mapped to PPA2, PANDAR/LAP3P2, POU6F1 and CTIF contained SNPs previously identified by CRC GWAS but with SNPs annotated to different genes. We found no evidence that any of the 19 mQTLs associated with CRC risk influenced survival or recurrence after FDR correction. Colocalisation analysis suggested that in three of the ten regions the causal variants were shared for methylation and CRC risk.

This study adds to the repertoire of CRC genes. However, we found no associations between methylation and CRC survival or recurrence.

## Linked entities

- **Genes:** MDGA2 (MAM domain containing glycosylphosphatidylinositol anchor 2) [NCBI Gene 161357], STARD3 (StAR related lipid transfer domain containing 3) [NCBI Gene 10948], POU5F1B (POU class 5 homeobox 1B) [NCBI Gene 5462], POU2AF2 (POU class 2 homeobox associating factor 2) [NCBI Gene 341032], POU2AF3 (POU class 2 homeobox associating factor 3) [NCBI Gene 120376], GREM1 (gremlin 1, DAN family BMP antagonist) [NCBI Gene 26585], CABLES2 (Cdk5 and Abl enzyme substrate 2) [NCBI Gene 81928], PPA2 (inorganic pyrophosphatase 2) [NCBI Gene 27068], PANDAR (promoter of CDKN1A antisense DNA damage activated RNA) [NCBI Gene 101154753], LAP3P2 (leucine aminopeptidase 3 pseudogene 2) [NCBI Gene 389386], POU6F1 (POU class 6 homeobox 1) [NCBI Gene 5463], CTIF (cap binding complex dependent translation initiation factor) [NCBI Gene 9811]
- **Diseases:** colorectal cancer (MONDO:0005575)

## Full-text entities

- **Genes:** POU5F1B (POU class 5 homeobox 1B) [NCBI Gene 5462] {aka OCT4-PG1, OCT4PG1, OTF3C, OTF3P1, POU5F1P1, POU5F1P4}, PANDAR (promoter of CDKN1A antisense DNA damage activated RNA) [NCBI Gene 101154753] {aka PANDA}, CTIF (cap binding complex dependent translation initiation factor) [NCBI Gene 9811] {aka Gm672, KIAA0427}, LAP3P2 (leucine aminopeptidase 3 pseudogene 2) [NCBI Gene 389386], PPA2 (inorganic pyrophosphatase 2) [NCBI Gene 27068] {aka HSPC124, SCFAI, SCFI, SID6-306}, POU6F1 (POU class 6 homeobox 1) [NCBI Gene 5463] {aka BRN5, MPOU, TCFB1}
- **Diseases:** CRC (MESH:D015179), cancer (MESH:D009369)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12356881/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12356881/full.md

## References

6 references — full list in the complete paper: https://tomesphere.com/paper/PMC12356881/full.md

---
Source: https://tomesphere.com/paper/PMC12356881